German officials are trying to stop the Trump administration from luring German biopharmeceutical company CureVac to the US to get its experimental coronavirus vaccines exclusively for Americans.

President Donald Trump has offered funds to lure the company CureVac to the US. The German government has made counter-offers to make the company stay, according to a report in German newspaper Welt am Sonntag.

An unidentified German government source told the paper Trump is trying to secure the scientists' work exclusively, and would do anything to get a vaccine for the United States - 'but only for the United States.'

CureVac said last week they are working on with a multitude of coronavirus vaccine candidates and are selecting the two best to go into clinical trials.

The company's CEO met with President Donald Trump and the White House Coronavirus Task Force to discuss a vaccine earlier this month.

German politicians are now insisting that no country should have a monopoly on any future vaccine.

DailyMail.com has reached out to the White House for comment.

German officials are trying to stop the US from enticing German company CureVac to move its research to the US, insisting no country should have a monopoly on any future vaccine. President Donald Trump had offered funds to lure the company CureVac to the US to reportedly get the vaccine exclusively for Americans

'The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe,' the newspaper quoted a Health Ministry official as saying.

'In this regard, the government is in intensive exchange with the company CureVac.'

A spokeswoman for the German Health Ministry said: 'We confirm the report in the Welt am Sonntag.'

The US Embassy in Berlin and CureVac is yet to comment on the report.

'The exclusive sale of a possible vaccine to the USA must be prevented by all means. Capitalism has limits,' Karl Lauterbach, a professor of health economics and epidemiology who is also a senior lawmaker with the Social Democrats, tweeted in reaction to the report.

Curevac is a private company founded in 2008 based in Tuebingen with other sites in Frankfurt and Boston.

CureVac said the company is getting ready to take experimental coronavirus vaccines to clinical trials, Florian von der Muelbe, CureVac's chief production officer and co-founder, said last week.

The company hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans.

Former CureVac CEO Daniel Menichella (right), accompanied by Robert Redfield, director of the Centers for Disease Control and Prevention (left), speaks during the White House meeting with pharmaceutical executives on March 2

'We believe we can develop the vaccine for COVID-19 very, very quickly, and we have the wherewithal to manufacture it, although we would like some additional help on our largest GMP fourth facility,' Menichella said at the White House meeting, nine days before he was replaced

Curevac is a private biopharmeceutical company founded in 2008 based in Tuebingen with other sites in Frankfurt and Boston

The company said that a mode of action that allowed for a low dosage to trigger an immune reaction against rabies would be applied in the coronavirus setting.

'These minimal dosages that we have achieved put us in a position here in Tuebingen to produce up to 10 million doses per (production) campaign,' von der Muelbe said of a potential vaccine.

A campaign, or production cycle, lasts several weeks.

'More than one dose may be required to immunize a person, but one campaign would still serve several million people,' he said.

Then-CureVac CEO Daniel Menichella met Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and senior representatives of pharmaceutical and biotech companies to discuss a vaccine at the White House on March 2.

'We believe we can develop the vaccine for COVID-19 very, very quickly, and we have the wherewithal to manufacture it, although we would like some additional help on our largest GMP fourth facility,' Menichella said at that meeting.

In the US as of Sunday morning there are over 2,900 cases of coronavirus and at least 58 deaths. People pictured wearing masks in New York City Saturday

This map shows the total number of coronavirus cases and deaths in the US as of Sunday

In that White House meeting the top executives from nearly a dozen biotech and pharmaceutical companies briefed Trump on their coronavirus drug development plans.

Menichella, who became CEO in May 2018, was abruptly replaced by board chairman Ingmar Hoerr just nine days after his DC meeting with Trump and drugmakers.

'We will continue to focus fully on taking the company to the next stage of its development and advance our clinical product pipeline with the goal of bringing mRNA-based drugs to patients. The vaccine against Covid-19 plays a key role here,' Hoerr said according to BioPharma Dive after Menichella was ousted.

CureVac specializes in RNA molecules that instruct human cells to produce therapeutic proteins that trigger an immune response to cancer or infection diseases.

CureVac was granted $8.3million by the Coalition for Epidemic Preparedness Innovations in January to build a solution based on its low-dose vaccine technology.

Dievini Hopp BioTech Holding and the Bill & Melinda Gates Foundation are two prominent investors in CureVac.

Top US health officials have said that it would take up to 18 months to develop any vaccine against the pathogen.